Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Serum Institue of India

- PMLiVE

Adding insult to injury

Hey Europe, it may be time to consider that ‘less is more’

- PMLiVE

Valneva to compare its COVID-19 vaccine candidate to AstraZeneca’s jab

Phase 3 trial will test Valneva’s vaccine candidate against Vaxzevria in approximately 4,000 participants

- PMLiVE

Oxford University, Prenetics to advance COVID-19 rapid testing for other infectious diseases

Rapid testing technology at the core of the collaboration is used in Oxford University's COVID-19 test

- PMLiVE

EMA finds overall benefit-risk ‘remains positive’ for J&J COVID-19 vaccine

Safety committee finds possible link to ‘very rare cases’ of unusual blood blots with low blood platelets

- PMLiVE

WHO director-general says pandemic can be brought under control within months

World has tools to curb pandemic if applied ‘consistently and equitably’

- PMLiVE

NICE sets out plans for ‘ambitious’ five-year strategy

NICE refocuses on reducing health inequalities and accelerating access to the latest and most effective treatments

- PMLiVE

UK-based challenge study to re-expose healthy adults to COVID-19

Study will enrol participants aged 18-30 who have previously been infected with COVID-19

- PMLiVE

Moderna COVID-19 vaccine shortfall could affect UK supply

But deliveries to the EU and Switzerland are not affected by the supply issues

- PMLiVE

Lilly asks to revoke emergency authorisation for bamlanivimab monotherapy in the US

Decision prompted by the ‘evolving variant landscape’ in the US

- PMLiVE

CureVac outlines COVID-19 vaccine production plans ahead of regulatory approval

Company is aiming to receive European approval in June

Effective Leadership During & After the COVID-19 Pandemic

Carol Stiff, Head of Canada at Santen, delves into what effective leadership looks like before, during, and after COVID-19; challenges brought on by the pandemic; the importance of developing partnerships...

Impetus Digital

- PMLiVE

Merck & Co halts development of potential COVID-19 drug MK-7110

Pharma company has abandoned drug due to technical, clinical and regulatory uncertainties

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links